Methods and compositions for treating leukemia are disclosed. Acylated 6-aminoindoles, acylated 6-aminopyrrolopyridines and acylated 3-aminopyrrolo[3,2-c]pyridazines of the following formula

##STR00001##

inhibit ENL/AF9 YEATS and are therefore useful for treating leukemia.

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

Provided herein are methods of treating a patient infected with a coronavirus and having a baseline level of CRP below 150 mg/L, comprising administering to the patient a compound of formula 1:

##STR00001##

or a pharmaceutically-acceptable salt thereof.

Provided herein are methods of treating a patient infected with a coronavirus and having a baseline level of CRP below 150 mg/L, comprising administering to the patient a compound of formula 1:

##STR00001##

or a pharmaceutically-acceptable salt thereof.

Provided herein are methods of treating a patient infected with a coronavirus and having a baseline level of CRP below 150 mg/L, comprising administering to the patient a compound of formula 1:

##STR00001##

or a pharmaceutically-acceptable salt thereof.

Disclosed are compounds of Formula (I′), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

##STR00001##

Disclosed are compounds of Formula (I′), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

##STR00001##

The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.

The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.